Answers are grounded in this paper and cite their sources.
Traditionally, clinicians recognize that patients, even with the same disease, may demonstrate vastly differing clinical phenotypes: observable features and symptoms at the individual level that account for disease heterogeneity. Although clinical phenotyping has advanced respiratory medicine, it alone provides an incomplete picture in relation to disease-specific functional and/or pathobiological mechanisms (endotypes) that vary among individuals. An individual presenting with a particular clinical phenotype can demonstrate multiple endotypes, while a single endotype may be present across a range of clinical phenotypes. Respiratory diseases including severe asthma, chronic obstructive pulmonary disease (COPD), and bronchiectasis all demonstrate inherent disease heterogeneity accounted for by their various endophenotypes, which in some instances has precluded the success of randomized clinical trials (1–4). One key approach to resolving endophenotyping in chronic respiratory disease is the use of multiomics. Our quest to realize precisionmedicine necessitates a combined view of clinical features and pathobiological assessment, including genomics, epigenomics, transcriptomics, metabolomics, lipidomics, proteomics, andmost recently microbiomics. Large-scale assessment of multiomics, including the NHLBI’s Trans-Omics for PrecisionMedicine program (5) and the UK Biobank (6), provide vast data for clinicians and scientists to work with, but the key challenge is developing, selecting, and applying appropriate methodology to holistically view such “big data” at the personal level and allow bedside clinical translation. Thus far, most endophenotyping efforts have focused on either a single omics or microbial kingdom, and therefore multiomics and/or multibiome assessment in respiratory disease remains limited. A multiomics approach integrating clinical parameters with the bacteriome, virome, transcriptome, andmetabolome in infants with respiratory syncytial virus identifies endotypes relating to risk of subsequent childhood asthma, while in bronchiectasis, multibiome (bacteria, viruses, and fungi) integration resolves a “high-risk” group characterized by increased exacerbations and intermicrobial cross-talk (7, 8). Importantly, microbiomics remains a field in rapid ascent, in which all microorganisms within a given community are assessed collectively. Considering strong emerging evidence for the importance of host–pathogen relationships in the pathogenesis and progression of chronic respiratory disease, studies assessing microbiomics in tandem with other host-derived omics are required. In this issue of the Journal, two studies are presented, both using microbiomics-focused data assessment together with other omics to resolve endophenotypes in bronchiectasis and COPD (9, 10). First, Huang and colleagues (pp. 417–426) reveal that individuals with COPD and COPD associated with bronchiectasis present with variable lung microbiome and host response profiles and that the underlying pathophysiology of the latter is most closely related to bronchiectasis. Combining sputum bacteriomes with label-free proteomics, they propose five endotypes, according to features with known prognostic implications in COPD and bronchiectasis, respectively, and differing by microbiome/proteome profiles (9). Each endotype reveals varied mechanisms between patients (with the same disease): some with features leaning toward COPD and others toward bronchiectasis, with each speculated to be “targetable” by different treatment approaches (indicated in parentheses). These include 1) diverse protective (no treatment), 2) diverse T-helper cell type 2 (inhaled corticosteroids), 3) infected epithelial response (macrolides), 4) proteobacteria neutrophilic (macrolides or dipeptidyl peptidase-1 inhibitors), and 5)Haemophilus proteolytic (antiinfective or antiinflammatory) groups (9). Critically, key findings related to the association of COPDwith bronchiectasis were independently validated (9). Using a different approach, Madapoosi and colleagues (pp. 427–439) evaluate paired bacteriome andmetabolomic data from BAL in ever-smokers in the SPIROMICS (Subpopulations and Intermediate OutcomeMeasures in COPD Study) cohort comparing individuals with or without mild to moderate COPD (i.e., Global Initiative for Chronic Obstructive Lung Disease groups 0–2) (10). Airway infection is linked to progressive COPD, but the role of airway microbes in milder disease has been unclear. SPIROMICS previously demonstrated, in independent studies, links between the lung microbiome and metabolome and clinical outcomes (11, 12). Here, presenting a combined, integrated analysis incorporating bacteriome sequencing, untargeted metabolomics (hydrophobic fraction of mainly lipids), and targeted metabolomics (mucoinflammatory panel of hydrophilic compounds), they reveal that specific microorganisms relate to COPD status, lung function, symptoms, and/or exacerbations, implying that lung bacteriomes and metabolomes, to different extents, influence pathogenesis in mild to moderate COPD (10). For instance, members of the Prevotella genus appear protective, demonstrating lower risks of COPD, higher lung function, andminimal symptoms. These bacteria are associated with metabolic signatures including adenosine, 5-methylthioadenosine, sialic acid, tyrosine, and glutathione. Conversely, other bacterial groups, including Streptococcus,Neisseria, andVeillonella, accompanied by elevated glycosphingolipids, glycerophospholipids, This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0. For commercial usage and reprints, please e-mail Diane Gern (dgern@thoracic.org).
No takes yet. Share an insight, caveat, or question.
Narayana et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: